60 Degrees Pharmaceuticals (SXTP) News Today → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free SXTP Stock Alerts $0.24 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadline60 Degrees Pharmaceuticals (NASDAQ:SXTP) Trading Up 2.7%americanbankingnews.com - April 27 at 3:00 AM60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 8.33% to 1.33msn.com - April 18 at 2:19 AM60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosisfinance.yahoo.com - April 3 at 9:00 AM60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosisglobenewswire.com - April 3 at 7:58 AM60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024globenewswire.com - March 14 at 7:59 AM60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisfinance.yahoo.com - February 20 at 8:29 AM60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisglobenewswire.com - February 20 at 7:59 AM60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officerfinance.yahoo.com - February 8 at 8:56 AM60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offeringfinance.yahoo.com - January 31 at 3:31 PMWallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offeringfinance.yahoo.com - January 31 at 3:31 PM60 Degrees Shares Plumb New Lows After Public Offeringmarketwatch.com - January 30 at 7:39 PM60 Degrees Pharmaceuticals Incmorningstar.com - January 30 at 2:39 PMWallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offeringfinance.yahoo.com - January 30 at 2:39 PMWhy Is 60 Degrees (SXTP) Stock Down 33% Today?markets.businessinsider.com - January 30 at 9:38 AM60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offeringfinance.yahoo.com - January 30 at 9:38 AM60 Degrees Pharmaceuticals files to sell 4.79M unitsmsn.com - January 22 at 6:10 PMWhy Is 60 Degrees Pharmaceuticals Stock Trading Higher Today?msn.com - January 22 at 6:10 PM60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDAmarketwatch.com - January 22 at 1:10 PM60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meetingfinance.yahoo.com - January 22 at 8:10 AM60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirementsfinance.yahoo.com - January 16 at 9:48 AM60 Degrees Pharmaceuticals Shares Surge 28% on Approved Study of Tafenoquine as Potential Bbesiosis Treatmentmarketwatch.com - December 28 at 6:05 PMWhy Is Infection Treatment Focused-60 Degrees Pharmaceuticals Stock Soaring Today?msn.com - December 26 at 1:44 PM60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024finance.yahoo.com - December 26 at 8:44 AM60 Degrees to meet with FDA over developing Arakoda for babesiosismsn.com - November 15 at 1:13 PM60 Degrees Pharmaceuticals, Inc. (SXTP)sg.finance.yahoo.com - November 15 at 8:13 AM60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Diseasefinance.yahoo.com - November 15 at 8:13 AMHold Rating Recommended for 60 Degrees Pharmaceuticals due to Uncertain Profitability and Strategic Shiftmarkets.businessinsider.com - October 20 at 10:23 AM60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Bostonfinance.yahoo.com - October 19 at 1:04 PM60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseasesfinance.yahoo.com - October 12 at 8:05 PMmarketbeat.com - October 12 at 4:17 PM60 Degrees Pharmaceuticals Inc.barrons.com - September 20 at 10:30 PMWhy Is Infectious Disease Focused 60 Degrees Pharmaceuticals Stock Trading Lower Today?msn.com - September 20 at 12:28 PM60 Degrees Pharma withdraws mid-stage study application for COVID drugreuters.com - September 18 at 5:55 PM60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirementsfinance.yahoo.com - September 18 at 5:55 PM60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 8:04 AMGenetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TVfinance.yahoo.com - September 1 at 6:03 PMGenetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TVfinance.yahoo.com - September 1 at 9:17 AM60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activityfinance.yahoo.com - August 30 at 8:46 AM60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malariafinance.yahoo.com - August 22 at 6:36 PM60 Degrees Pharmaceuticals Inc (SXTP)uk.investing.com - August 15 at 10:19 PM60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govfinance.yahoo.com - August 15 at 12:17 PM60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjectsfinance.yahoo.com - August 14 at 8:29 AMWhy Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 17% Today?investorplace.com - July 13 at 10:08 AMmarketbeat.com - July 13 at 9:48 AMmarketbeat.com - July 13 at 9:31 AM Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work? Click Here To Get Your Free Copy SXTP Media Mentions By Week SXTP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼-0.500.33▲Average Medical News Sentiment SXTP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼21▲SXTP Articles Average Week Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARAV News Today ARDS News Today AGRX News Today ONCO News Today RNAZ News Today CWBR News Today REVB News Today SNOA News Today BCEL News Today BPTS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
